

Product datasheet for TG320519

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

RPS6KA3 Human shRNA Plasmid Kit (Locus ID 6197)

Product data:

Product Type: shRNA Plasmids

Product Name: RPS6KA3 Human shRNA Plasmid Kit (Locus ID 6197)

Locus ID: 6197

Synonyms: CLS; HU-3; ISPK-1; MAPKAPK1B; MRX19; p90-RSK2; pp90RSK2; RSK; RSK2; S6K-alpha3

Vector: pGFP-V-RS (TR30007)

E. coli Selection: Kanamycin

Mammalian Cell Puromycin

Selection:

Format: Retroviral plasmids

Components: RPS6KA3 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID =

6197). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free.

RefSeq: NM 004586, NM 004586.1, NM 004586.2, BC096301, BC015451, BC096302, BC096303,

NM 004586.3

UniProt ID: P51812

Summary: This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine

kinases. This kinase contains 2 non-identical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Mutations in this gene have been associated with Coffin-Lowry syndrome

(CLS). [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).